HNHideki Nakahara

Hideki Nakahara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hideki Nakahara has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synchronous double primary hepatic cancer consisting of hepatocellular carcinoma and cholangiolocellular carcinoma: a case report

    by Masateru Yamamoto, Akihiko Oshita, Takashi Nishisaka, Hideki Nakahara, Toshiyuki Itamoto

    The incidence of synchronous double primary hepatic cancers is extremely low. Cholangiolocellular carcinoma is also a rare disease. A 58-year-old Japanese man was referred to our hospital for the treatment of multiple liver tumors revealed on computed tomography scans. He was hepatitis B and C positive and had undergone hemodialysis for 9 years due to chronic renal failure. Computed tomography scans revealed two hepatic tumors (each ≤ 1.0 cm in diameter) in segments 3 and 7. The preoperative diagnosis was multiple hepatocellular carcinomas. He underwent partial resections of his liver. The resected specimens revealed that the tumors in segments 3 and 7 were well-defined lesions of 8.0 mm and 14.0 mm, respectively. Pathological and immunohistochemical examinations confirmed the tumor in segment 3 to be a cholangiolocellular carcinoma and the tumor in segment 7 to be a hepatocellular carcinoma. Chronic inflammation could contribute to the different types of primary hepatic cancers. It may also give rise to various combinations of synchronous double primary hepatic cancer in patients with chronic liver disease. We describe the sixth case of synchronous double primary hepatic cancers consisting of hepatocellular carcinoma and cholangiolocellular carcinoma in chronic damaged liver and review the literature. In patients with chronic liver disease, careful surveillance with imaging studies should be mandatory as various types of primary hepatic cancers could develop.


  • Lymph node dissection of the suprapancreatic area was performed with the medial approach

    by Takashi Urushihara, Noriaki Tokumoto, Yuji Takakura, Akihiko Oshita, Satoshi Ikeda, Yasuhiro Matsugu, Hideki Nakahara, Toshiyuki Itamoto

  • Set up of a multi-channel platform and abdominal wall lifting, and lymphadenectomy of No. 4sb, No. 6 and No. 5 in RPG

    by Takashi Urushihara, Noriaki Tokumoto, Yuji Takakura, Akihiko Oshita, Satoshi Ikeda, Yasuhiro Matsugu, Hideki Nakahara, Toshiyuki Itamoto

  • Reconstruction was performed with functional endto-end anastomosis; gastroduodenostomy, with the Billroth-I method by using an endolinear stapler

    by Takashi Urushihara, Noriaki Tokumoto, Yuji Takakura, Akihiko Oshita, Satoshi Ikeda, Yasuhiro Matsugu, Hideki Nakahara, Toshiyuki Itamoto

  • X-technique, in which two straight forceps are crossed over through the platform to make a reverse triangulation

    by Takashi Urushihara, Noriaki Tokumoto, Yuji Takakura, Akihiko Oshita, Satoshi Ikeda, Yasuhiro Matsugu, Hideki Nakahara, Toshiyuki Itamoto

    • 1 May 2014
      • Vol. 41  (5) , 595-600

    [Estimation of peritoneal dissemination in patients with unresectable advanced or recurrent colorectal cancer who underwent curative resection after combination chemotherapy].

    by Shinori Mizota, Satoshi Ikeda, Masami Yamauchi, Yuki Imaoka, Hiroaki Mashima, Sho Okimoto, Yuji Takakura, Midori Noma, Masahiro Ohara, Koichi Oishi, et al.

    In a group of 209 colorectal cancer patients with unresectable tumors, 10 patients underwent curative resection after combination chemotherapy at our hospital between 2006 and 2012. Of these 10 patients, 5 presented with peritoneal dissemination at the start of chemotherapy. With the exception of 1 patient with peritoneal recurrence, peritoneal dissemination and liver metastasis were observed in all patients at the time of diagnosis of colorectal cancer. Computed tomography (CT) and/ or positron emission tomography-CT examination revealed disappearance of peritoneal dissemination in response to chemotherapy, except in 1 patient with peritoneal recurrence. After combination chemotherapy, surgical resection of liver metastases and peritoneal dissemination was performed. Pathological and intraoperative findings indicated disappearance of peritoneal dissemination in 3 patients and P2 grade peritoneal dissemination in 1 patient. In the patient with peritoneal recurrence, 1 tumor was completely resected. Interestingly, none of the 3 patients that exhibited complete disappearance of peritoneal dissemination showed peritoneal recurrence, although 1 patient exhibited metastases in the lung and non-regional lymph nodes. In contrast, the patient with P2 grade peritoneal dissemination showed peritoneal recurrence and lung metastasis. All 5 patients survived (duration from diagnosis of colorectal cancer, 31-83 months). Herein, we report the use of combination chemotherapy to achieve the disappearance of peritoneal dissemination, changing unresectable colorectal cancer with peritoneal dissemination into resectable cancer.

    • 1 April 2014
      • Vol. 41  (4) , 483-6

    [A case of triple-negative breast cancer responding to multidisciplinary treatment containing bevacizumab].

    by Midori Noma, Masahiro Ohara, Yuki Imaoka, Hirosato Mashima, Shinori Mizota, Sho Okimoto, Yuji Takakura, Koichi Oishi, Toshihiko Kohashi, Satoshi Ikeda, et al.

    We report a case of a 64-year-old woman with Stage IV breast cancer who responded well to chemotherapy containing bevacizumab. She noticed a left breast tumor with acute progression and was diagnosed as having Stage IV, estrogen receptor( ER)(-), progesterone receptor(PgR)(-), human epidermal growth factor receptor 2(HER2)(-)breast cancer (T4cN3cM1[lymph nodes]). She received 5 courses of adriamycin(60mg/m / 2)plus cyclophosphamide(600mg/m2)(AC therapy)and 4 courses of weekly paclitaxel(PTX 90mg/m / 2)plus bevacizumab(AVA 10 mg/m2)as systemic therapy. Computed tomography(CT)and magnetic resonance imaging(MRI)revealed a complete response(CR). After local resection of the breast tumor and radiation to the breast and regional lymph nodes, capecitabine therapy was initiated. Currently, at 5 months after surgery, no new lesion has been detected.

    • 1 November 2009
      • Vol. 36  (11) , 1911-4

    [A case of advanced rectal cancer that responded to S-1 with an extended complete response].

    by Hiroyuki Egi, Masazumi Okajima, Yuji Takakura, Hideki Nakahara, Yasuhiro Matsugu, Toshihiko Kohashi, Takayuki Kadoya, Ichiro Ohmori, Takashi Urushihara, Toshiyuki Itamoto

    A 78-year-old female underwent an abdomino-perineal resection for lower rectal cancer with para-aortic, right iliac artery and left inguinal lymph node metastasis. Two weeks later, an enlargement of para-aortic and right iliac artery lymph node metastasis was detected by CT. S-1 (100 mg/day for 2 weeks followed by a 1-week rest period) + CPT-11 (120 mg/m2, day 1)treatment was initially administered. However, the patient developed grade 2 anorexia so this treatment regimen was terminated. After complete recovery from the adverse reaction, the regimen was converted to S-1 administration at 100mg/day S-1 for 2 weeks followed by a 1-week rest period. Eventually, this schedule was modified to 100mg/day for 1 week followed by a 1-week rest period. A year after the operation, CT revealed the lymph node metastasis to have disappeared, and no relapse occurred for 32 months. This was a successful case in which S-1 yielded an extended complete response for advanced rectal cancer. Treatment with S-1 is an effective choice for patients who for various reasons can not tolerate the standard treatment for unresectable advanced colorectal cancer. Moreover, randomized controlled trials have to be started to evaluate the efficacy of S-1 treatment for advanced rectal cancer as soon as possible.

  • Indication of Hepatectomy for Cirrhotic Patients with Hepatocellular Carcinoma Classified as Child‐Pugh Class B

    by Hideki Nakahara, Toshiyuki Itamoto, Koji Katayama, Hideki Ohdan, Hiroshi Hino, Makoto Ochi, Hirotaka Tashiro, Toshimasa Asahara

    We clarified the indication of partial hepatectomy in hepatocellular carcinoma (HCC) patients with liver cirrhosis classified as Child-Pugh class B. Univariate analysis revealed that adverse prognostic factors were (1) the presence of ascites, (2) elevated total bilirubin (1.5 mg/dl or higher), (3) reduced choline esterase (160 IU/ or lower), (4) elevated alpha-fetoprotein (AFP) (400 ng/ml or higher), (5) microscopic vascular invasion, and (6) non-curative hepatectomy. Microvascular invasion was excluded in the multivariate analysis because this factor could not be predicted before hepatectomy. Multivariate analysis revealed that independent adverse prognostic factors were (1) elevated total bilirubin (1.5 mg/dl or higher), (2) presence of ascites, (3) elevated AFP (400 ng/ml or higher), and (4) non-curative hepatectomy. The overall 5-year survival rate of patients with none of or only one of the four adverse prognostic factors was 45.8%. The overall 5-year survival rate of patients with two or more adverse prognostic factors was only 7.0%. Partial hepatectomy is the first choice of treatment for patients with none of or only one of the four adverse prognostic factors, whereas orthotopic liver transplantation or other conservative treatment should be considered for patients with two or more adverse prognostic factors.